<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35552737</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1943-7730</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Laboratory medicine</Title>
          <ISOAbbreviation>Lab Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Macroprolactinoma-Induced Syndrome of Inappropriate Antidiuresis and Its Reversal with Dopamine Agonist Therapy.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">lmac025</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/labmed/lmac025</ELocationID>
        <Abstract>
          <AbstractText>Hyponatremia is an uncommon manifestation of pituitary adenomas. Herein, I report a case of syndrome of inappropriate antidiuresis (SIAD) caused by a macroprolactinoma that rapidly resolved with dopamine agonist therapy. A 29-year-old White woman presented with euvolemic, hypotonic hyponatremia, normal thyroid and glucocorticoid axes, and inappropriately concentrated urine. She was found to have a 1.2-cm sellar mass. Investigation of additional pituitary axes revealed an elevated prolactin level of 193.7 ng/mL. The SIAD experienced by the patient corrected rapidly with initiation of cabergoline. The patient could not tolerate dopamine agonist therapy, and after 1 year, she underwent transsphenoidal resection of the mass after the prolactin began to increase. Pathological examination confirmed the diagnosis of macroprolactinoma. There was no recurrence of the tumor, and the patient continued to have normonatremia and normoprolactinemia 7 years after her operation. To my knowledge, this is the first report in the literature of pathology-confirmed macroprolactinoma marked by SIAD that showed rapid normalization of water metabolism with dopamine agonist therapy.</AbstractText>
          <CopyrightInformation>Â© The Author(s) 2022. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schlegel</LastName>
            <ForeName>Amnon</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-4060-2252</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Lab Med</MedlineTA>
        <NlmUniqueID>0250641</NlmUniqueID>
        <ISSNLinking>0007-5027</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">SIAD</Keyword>
        <Keyword MajorTopicYN="N">SIADH</Keyword>
        <Keyword MajorTopicYN="N">cabergoline</Keyword>
        <Keyword MajorTopicYN="N">hyponatremia</Keyword>
        <Keyword MajorTopicYN="N">prolactinoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>14</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35552737</ArticleId>
        <ArticleId IdType="doi">10.1093/labmed/lmac025</ArticleId>
        <ArticleId IdType="pii">6585450</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
